Agarwal Drug Distributors Profile
Key Indicators
- Authorised Capital ₹ 1.80 Cr
as on 17-11-2024
- Paid Up Capital ₹ 1.67 Cr
as on 17-11-2024
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.93 Cr
as on 17-11-2024
- Revenue 0.83%
(FY 2023)
- Profit -9.82%
(FY 2023)
- Ebitda 11.79%
(FY 2023)
- Net Worth 6.37%
(FY 2023)
- Total Assets -7.16%
(FY 2023)
About Agarwal Drug Distributors
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.80 Cr and a paid-up capital of Rs 1.67 Cr.
The company currently has active open charges totaling ₹5.93 Cr.
Sanjiv Badhan and Rajiv Badhan serve as directors at the Company.
- CIN/LLPIN
U24239WB2005PTC103975
- Company No.
103975
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jul 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Agarwal Drug Distributors?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjiv Badhan  | Director | 01-Jul-2005 | Current |
| Rajiv Badhan | Director | 01-Jul-2005 | Current |
Financial Performance and Corporate Structure Insights of Agarwal Drug Distributors.
Agarwal Drug Distributors Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.83% increase. The company also saw a slight decrease in profitability, with a 9.82% decrease in profit. The company's net worth moved up by a moderate rise of 6.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agarwal Drug Distributors?
In 2023, Agarwal Drug Distributors had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Visionary Hospitality Private LimitedActive 11 years 9 monthsSanjiv Badhan and Rajiv Badhan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Jun 2024 | ₹3.20 M | Open |
Others Creation Date: 12 Jun 2024 | ₹0.98 M | Open |
Others Creation Date: 15 Jun 2021 | ₹0.79 M | Open |
How Many Employees Work at Agarwal Drug Distributors?
Agarwal Drug Distributors has a workforce of 46 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agarwal Drug Distributors, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agarwal Drug Distributors's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
